Key Developments: CSL Ltd (CSL.AX)
57.34AUD
19 Jun 2013
$-0.66 (-1.14%)
$58.00
$57.50
$57.86
$56.15
2,010,121
1,348,044
$64.70
$37.69
Latest Key Developments (Source: Significant Developments)
CSL Ltd Closes New USD500 Million Private Placement
CSL Ltd announced that on March 27, 2013 it closed a new USD500 million Private Placement in the US. The Private Placement consists of four maturities, as follows: USD100 million for 5 years bullet with coupon value 2.07%; USD150 million for 7 years bullet with coupon value 2.57%; USD150 million for 10 years bullet with coupon value 3.20%; USD100 million for 12 years bullet with coupon value 3.32%. The Private Placement has a weighted average interest rate of 2.81% and average life of 8.5 years. The proceeds from the Private Placement will be used to fund the Group’s capital management plan, including on-market buybacks, and for general corporate purposes. Full Article
CSL Ltd Announces H1 2013 Interim Dividend
CSL Limited announced the proposed interim dividend of USD 0.50, expected to be paid on April 5, 2013 out of retained earnings at 31 December 2012. Full Article
CSL Ltd Raises FY 2013 Profit Guidance
CSL Ltd announced a revised USD profit outlook for fiscal 2013. The Company now expects net profit after tax to grow by approximately 20% at constant currency, despite competitive business conditions. In August 2012, the Company reported a net profit after tax of USD 1,024 million and provided guidance that it expected profit to grow approximately 12% during fiscal 2013. Full Article
CSL Ltd Announces FY 2012 Final Dividend
CSL Ltd announced a final dividend of AUD 0.47 per share for fiscal 2012. The record date is September 21, 2012 and the payment date is October 12, 2012. Full Article
CSL Ltd's CSL Biotherapies Secures US Government Contract For Influenza Pandemic Preparedness And Response
CSL Ltd's CSL Biotherapies announced that it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile. Under the terms of the contract, the U.S. Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The Company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen. Full Article
CSL Ltd Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call
CSL Ltd announced that for fiscal 2013, it expects revenue from the group of approximately 10% and that means that at constant currency approximately $5 billion business. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of AUD5.004 billion for fiscal 2013. Full Article
CSL Ltd Announces FY 2012 Final Dividend
CSL Ltd announced a final dividend of AUD 0.27 per share for fiscal 2012 (FY 2011: AUD 0.45 per share). The record date is September 21, 2012 and the payment date is October 12, 2012. Full Article
CSL Limited Announces Announces Change Of Chief Executive Officer
CSL Limited announced that Dr. Brian McNamee, AO, has agreed with the Board of Directors the timing of the handover to his successor as Chief Executive Officer (CEO) and Managing Director. Dr. McNamee will leave CSL in July 2013 and will be succeeded by Paul Perreault, the President of CSL Behring. Full Article
BlackRock Group Ceases To Be Substantial Shareholder Of CSL Limited
CSL Limited announced that BlackRock Group ceased to be substantial shareholder of the Company on June 30, 2012. Full Article
CSL Limited Announces H1 2012 Dividend
CSL Limited announced an interim dividend of AUD 0.36 per share, unfranked for the first half of fiscal 2012. The record date is March 20, 2012 and the dividend will be paid on April 13, 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
